Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non‐Hodgkin Lymphoma
Lymphoma, a common malignancy of the lymphatic system, presents considerable health challenges and imposes a significant economic burden. Despite advancements in chemotherapy and immunotherapy that have improved survival rates, issues such as high relapse rates and treatment resistance remain pressing concerns. This study presents a novel therapeutic strategy that combines rituximab with a therapeutic vaccine for human B-cell non-Hodgkin lymphoma, evaluated in a humanized mouse model. This combination therapy synergistically achieves superior tumor suppression and relapse prevention. By harnessing the tumor-killing efficacy of monoclonal antibodies and the T cell-mediated immunity elicited by vaccines, this approach represents a promising advancement in achieving significantly improved cancer treatment outcomes.
Authors
- Emiko Kranz
- Zheng Cao (ORCID: https://orcid.org/0000-0003-1242-3513)
- Cun‐yu Wang
- Jing Wen (ORCID: https://orcid.org/0000-0002-6127-6276)
- Yunfeng Lu (ORCID: https://orcid.org/0000-0002-8589-0297)
- E Kimura
- Jimin Guo (ORCID: https://orcid.org/0000-0002-8249-1880)
- Tong Qi (ORCID: https://orcid.org/0009-0005-2198-5157)
- Zi Wang (ORCID: https://orcid.org/0000-0002-3881-2544)
- Guo Xin-Heng
- Wenting Chen (ORCID: https://orcid.org/0000-0001-8232-9421)
- Shilin Chen (ORCID: https://orcid.org/0000-0002-0449-236X)
- Xiyao Li (ORCID: https://orcid.org/0000-0002-5767-5039)
Institutions
- University of California, Los Angeles (US)
- Black AIDS Institute (US)
- Beijing University of Chemical Technology (CN)
Publication Details
- Journal
- Advanced Materials
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1002/adma.202502372
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- James B. Pendleton Charitable Trust
- National Institutes of Health
- Clinical and Translational Science Institute, University of California, Los Angeles
- UCLA AIDS Institute